keyword
MENU ▼
Read by QxMD icon Read
search

dlqi

keyword
https://www.readbyqxmd.com/read/28646610/measuring-the-societal-impact-of-psoriasis-in-the-united-kingdom-through-a-non-interventional-study-of-patients
#1
C E Griffiths, R Williams, A C Halliday, J A Leman
This cross-sectional study aimed to measure total societal costs of moderate-to-severe, chronic plaque psoriasis in adults, and was conducted at 10 National Health Service hospitals in the United Kingdom between June-November 2014. Data capture was via hand-held electronic devices. Investigators at participating sites identified participants. Eligible patients were ≥18 years of age and diagnosed with moderate-to-severe plaque psoriasis for at least 6 months (Psoriasis Area and Severity Index (PASI) ≥10, and Dermatology Life Quality Index (DLQI) >10)...
June 24, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28644904/sustained-pasi-dlqi-and-eq-5d-response-of-biological-treatment-in-psoriasis-10-years-of-real-world-data-in-the-swedish-national-psoriasis-register
#2
F Hjalte, K Steen Carlsson, M Schmitt-Egenolf
BACKGROUND: Few studies have analysed the long-term effects of biological treatment in psoriasis. PsoReg, the Swedish national register for systemic psoriasis treatment, started in 2006 and includes now ten years of real-world data on effectiveness of biological treatment. OBJECTIVE: To analyse long-term real-world outcome data on biological-naïve patients with moderate to severe psoriasis after switching to biological treatment. METHODS: Observational study including biological-naïve patients with at least one registration of outcome before switching to biological treatment while included in PsoReg and at least one follow-up visit...
June 23, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28624255/-psoriatic-patients-analysis-of-patients-dissatisfied-with-their-management
#3
E Mahé, F Maccari, A Beauchet, N Quiles-Tsimaratos, N Beneton, J Parier, H Barthelemy, C Goujon-Henry, G Chaby, D Thomas-Beaulieu, G Géner, L Wagner, V Pallure, S Devaux, A Vermersch-Langlin, P Pfister, J Jégou, C Livideanu, M-L Sigal
BACKGROUND: The French are frequently regarded as grouchy. In a recent study, we observed a high proportion of patients initially consulting for psoriasis because they were dissatisfied with their previous therapy. We analyzed the characteristics of these patients. PATIENTS AND METHODS: This was a cross-sectional multicenter study in 40 centers belonging to the ResoPso (psoriasis treatment network) multicenter study group, with consecutive inclusions over a period of 11months in 2014...
June 14, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28617145/defining-treatment-success-in-rosacea-as-clear-may-provide-multiple-patient-benefits-results-of-a-pooled-analysis
#4
Guy Webster, Martin Schaller, Jerry Tan, J Mark Jackson, Nabil Kerrouche, Gregor Schäfer
Background Rosacea treatment success is usually defined as a score of 1 ("almost clear") or 0 ("clear") on the 5-point Investigator Global Assessment (IGA) scale. Objective To evaluate whether after successful treatment, "clear" subjects had better outcomes than "almost clear" subjects. Methods A pooled analysis was performed on 1366 rosacea subjects from 4 randomized controlled trials with IGA before and after treatment (ivermectin, metronidazole or vehicle). Assessments included the Dermatology Life Quality Index (DLQI) questionnaire and subject assessment of rosacea improvement...
June 15, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28611997/the-burden-of-hidradenitis-suppurativa-in-a-cohort-of-patients-in-southern-finland-a-pilot-study
#5
Nicolas Kluger, Martta Ranta, Martina Serlachius
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that impacts the quality of life. METHODS: We evaluated its burden in a cohort of 26 Finnish patients in a single-center cross-sectional study. Demographic data, disease history, clinical data, treatment patterns, and workability were collected. Patients responded to the Dermatology Life Quality Index (DLQI) and Beck Depression Inventory (BDI-21). RESULTS: Mean age of HS patients was 44...
March 2017: Skin Appendage Disorders
https://www.readbyqxmd.com/read/28601958/mapping-of-the-dlqi-scores-to-eq-5d-utility-values-using-ordinal-logistic-regression
#6
Faraz Mahmood Ali, Richard Kay, Andrew Y Finlay, Vincent Piguet, Joerg Kupfer, Florence Dalgard, M Sam Salek
PURPOSE: The Dermatology Life Quality Index (DLQI) and the European Quality of Life-5 Dimension (EQ-5D) are separate measures that may be used to gather health-related quality of life (HRQoL) information from patients. The EQ-5D is a generic measure from which health utility estimates can be derived, whereas the DLQI is a specialty-specific measure to assess HRQoL. To reduce the burden of multiple measures being administered and to enable a more disease-specific calculation of health utility estimates, we explored an established mathematical technique known as ordinal logistic regression (OLR) to develop an appropriate model to map DLQI data to EQ-5D-based health utility estimates...
June 10, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28589618/comparison-of-different-regimens-of-pimecrolimus-1-cream-in-the-treatment-of-facial-seborrheic-dermatitis
#7
Juemin Zhao, Wenjia Sun, Chengfeng Zhang, Jiaqiang Wu, Yan Le, Chunyun Huang, Ye Liu, Leihong Xiang
BACKGROUND: Pimecrolimus 1% cream has already been proved to be an effective and safe alternative to treat seborrheic dermatitis. However, the treatment periods were inconstant in previous studies. OBJECTIVE: To evaluate the comparative efficacy of pimecrolimus 1% cream with different regimens for the treatment of facial seborrheic dermatitis. METHOD: Thirty patients with facial seborrheic dermatitis were enrolled and randomly distributed to three groups...
June 7, 2017: Journal of Cosmetic Dermatology
https://www.readbyqxmd.com/read/28580646/secukinumab-is-superior-to-fumaric-acid-esters-in-treating-subjects-with-moderate-to-severe-plaque-psoriasis-who-are-na%C3%A3-ve-to-systemic-treatments-results-from-the-randomized-controlled-prime-trial
#8
M Sticherling, U Mrowietz, M Augustin, D Thaçi, N Melzer, C Hentschke, J Kneidl, C Sieder, K Reich
BACKGROUND: Secukinumab is a fully human antibody that neutralizes IL-17A and has significant efficacy and a favorable safety profile in moderate to severe plaque psoriasis and psoriatic arthritis. METHODS: In this 24-week, randomized, open-label, multicenter study with blinded assessment, subjects with moderate to severe plaque psoriasis, naïve to systemic treatments, were randomized to receive secukinumab 300 mg subcutaneously or oral fumaric acid esters (FAE)...
June 5, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28573743/impact-of-ixekizumab-treatment-on-skin-related-personal-relationship-difficulties-in-moderate-to-severe-psoriasis-patients-12-week-results-from-two-phase-3-trials
#9
L Guenther, R B Warren, J C Cather, H Sofen, Y Poulin, M Lebwohl, T Terui, A Potts Bleakman, B Zhu, R Burge, K Reich, P van de Kerkhof
BACKGROUND: Psoriasis symptoms may decrease quality of life for patients. Skin-related personal relationship difficulties in psoriasis patients are common, under-reported, and poorly understood. OBJECTIVE: To assess the effect of ixekizumab (IXE) treatment on skin-related personal relationship difficulties in patients with moderate-to-severe psoriasis. METHODS: Pooled data (N=2570) on skin-related relationship problems were obtained from two large phase 3 trials (UNCOVER-2 and UNCOVER-3) in patients with moderate-to-severe plaque psoriasis randomized to subcutaneous placebo (PBO, N=361), etanercept (ETN; 50 mg twice weekly, N=740), or 80 mg IXE as one injection every 4 (IXEQ4W, N=733) or 2 weeks (IXEQ2W, N=736) for 12 weeks, following a 160-mg initial dose...
June 2, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28573683/omalizumab-substantially-improves-dermatology-related-quality-of-life-in-patients-with-chronic-spontaneous-urticaria
#10
Andrew Y Finlay, Allen P Kaplan, Lisa A Beck, Evgeniya N Antonova, Maria-Magdalena Balp, James Zazzali, Sam Khalil, Marcus Maurer
BACKGROUND: Chronic spontaneous/idiopathic urticaria (CSU/CIU) has substantial detrimental effects on health-related quality of life (HRQoL) with an effect comparable to or worse than many other skin diseases. OBJECTIVE: To assess the effect of omalizumab on CSU patients' HRQoL, measured by the Dermatology Life Quality Index (DLQI) in three phase III studies ASTERIA I, ASTERIA II, and GLACIAL. METHODS: A post-hoc analysis examined changes in DLQI scores, distribution of patients across DLQI bands and the proportion reaching minimal clinically important difference (MCID) following omalizumab vs placebo...
June 2, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28570163/direct-access-online-care-for-the-management-of-atopic-dermatitis-a-randomized-clinical-trial-examining-patient-quality-of-life
#11
Heather Kornmehl, Sanminder Singh, Mary Ann Johnson, April W Armstrong
BACKGROUND: Atopic dermatitis (AD) is a chronic disease requiring regular follow-up. To increase access to dermatological care, online management of AD is being studied. However, a critical knowledge gap exists in determining AD patients' quality of life in direct-to-patient online models. In this study, we examined quality of life in AD patients managed through a direct-access online model. MATERIALS AND METHODS: We randomized 156 patients to receiving care through a direct-access online platform or in person...
June 1, 2017: Telemedicine Journal and E-health: the Official Journal of the American Telemedicine Association
https://www.readbyqxmd.com/read/28567556/minimal-disease-activity-in-patients-with-psoriatic-arthritis-treated-with-ustekinumab-results-from-a-24-week-real-world-study
#12
Maddalena Napolitano, Luisa Costa, Francesco Caso, Matteo Megna, Raffaele Scarpa, Nicola Balato, Fabio Ayala, Anna Balato
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease affecting around 40% of psoriasis patients. Minimal disease activity (MDA) criteria have been proposed to identify a state of low disease activity, one of the principal goals of treatment for psoriatic disease. This study investigated treatment with ustekinumab (UST) in the context of a real-world setting. Thirty-four PsA patients who had failure or inadequate response to conventional synthetic disease-modifying antirheumatic drugs or to anti-tumour necrosis factor alpha were enrolled...
May 31, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28542874/comparison-of-ixekizumab-with-ustekinumab-in-moderate-to-severe-psoriasis-24-week-results-from-ixora-s-a-phase-3-study
#13
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm, S Hartz, C Paul
BACKGROUND: The interleukin (IL)-23/IL-17 axis has been shown critical in the pathogenesis of psoriasis. OBJECTIVES: To present the primary endpoint (Week 12) and safety/efficacy data up to Week 24 from a head-to-head trial (IXORA-S) of the IL-17A inhibitor, ixekizumab (IXE), vs. the IL-12/23 inhibitor ustekinumab (UST). METHODS: Randomised patients received IXE (160-mg starting dose, then 80 mg every two weeks for 12 weeks, then 80 mg every four weeks, N=136) or UST (45 mg/90 mg weight-based dosing per label, N=166)...
May 19, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28541870/palmoplantar-pustulosis-a-cross-sectional-analysis-in-germany
#14
Dagmar Wilsmann-Theis, Arnd Jacobi, Yvonne Frambach, Sandra Philipp, Ansgar Weyergraf, Tillmann Schill, Kirsten Steinz, Sascha Gerdes, Rotraut Mössner
BACKGROUND: Palmoplantar pustulosis (PPP) is a recalcitrant chronic inflammatory skin disease. Data relevant for the medical care of patients with PPP are scarce. Thus, the aim of this work was to investigate the disease burden, clinical characteristics, and comorbidity of PPP patients in Germany. PATIENTS AND METHODS: PPP patients were examined in a crosssectional study at seven specialized psoriasis centers in Germany. RESULTS: Of the 172 included patients with PPP, 79...
April 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28540870/atorvastatin-as-adjunctive-therapy-for-chronic-plaque-type-psoriasis-versus-betamethasone-valerate-alone-a-randomized-double-blind-placebo-controlled-trial
#15
Sharlene Helene H Chua, Giselle Marie S Tioleco, Carmela Augusta F Dayrit, Winlove P Mojica, Belen L Dofitas, Lorna F Frez
BACKGROUND: Psoriasis is a T helper 1 cell-mediated chronic inflammation. Statins have been found to have anti-inflammatory and immunomodulatory effects targeting T helper 1 cells and thus, are being investigated as treatments for psoriasis. AIMS: To investigate the efficacy and safety of atorvastatin as adjunctive treatment for mild to moderate chronic plaque psoriasis; and the impact of atorvastatin on quality of life. The study also aimed to correlate the beneficial effects of atorvastatin with its lipid-lowering effects...
July 2017: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/28538875/particular-characteristics-of-atopic-eczema-in-tropical-environments-the-tropical-environment-control-for-chronic-eczema-and-molecular-assessment-teccema-cohort-study
#16
Jorge Sánchez, Andrés Sánchez, Ricardo Cardona
Background: Atopic dermatitis is a prevalent health problem in the world. Allergic sensitization is an important risk factor, but the roles of other factors, inherent in tropic region, are unknown. Objective: A cohort study was designed in a tropical city to investigate molecular and environmental risk factors for eczema, considering as particular features perennial exposure to mites, poor living conditions and others tropical characteristics. Methods: 433 patients were included at baseline and biological samples were collected during 24 months of follow-up...
March 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28507497/sense-of-coherence-as-a-protective-factor-in-chronic-urticaria
#17
Alicja Ograczyk, Joanna Miniszewska, Anna Pietrzak, Anna Zalewska-Janowska
INTRODUCTION: Chronic urticaria (CU) seems to be perceived as a psychodermatological disorder. Different psychological factors play an important role in CU triggering and course. One of them is a sense of coherence (SOC), which is believed to be a protective factor against anxiety and depression. AIM: To investigate quality of life (QoL) in CU patients and to compare selected psychological parameters (anxiety, depression and sense of coherence) between CU individuals and the control group...
April 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28489479/biologics-and-dermatology-life-quality-index-dlqi-in-the-australasian-psoriasis-population
#18
Diana Norris, Louise Photiou, Mark Tacey, Con Dolianitis, George Varigos, Peter Foley, Chris Baker
BACKGROUND/OBJECTIVES: Psoriasis is a chronic condition that may require long-term treatment for disease control. This analysis utilises data from the Australasian Psoriasis Registry with particular attention to the impact of biologic therapy on DLQI, and the differences between the biologics in terms of DLQI score change. METHODS: A retrospective review of patients enrolled in the Australasian Psoriasis Registry from April 2008 to August 2016 was conducted. All subjects from the registry that had DLQI and Psoriasis Assessment Severity Index (PASI) scores recorded at a baseline timepoint of treatment commencement, in addition to week 12 and 24 post commencement were included in the study...
May 10, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28482858/tight-controlled-dose-reduction-of-biologics-in-psoriasis-patients-with-low-disease-activity-a-randomized-pragmatic-non-inferiority-trial
#19
Selma Atalay, Juul M P A van den Reek, Lieke J van Vugt, Marisol E Otero, Peter C M van de Kerkhof, Alfons A den Broeder, Wietske Kievit, Elke M G J de Jong
BACKGROUND: Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic therapies became available in the last 10 years. Data from patients with rheumatoid arthritis revealed that dose tapering combined with tight control of disease activity is successful. For psoriasis patients the lowest effective dose of biologics needs to be determined. The objective was to assess whether dose tapering of biologics guided by Psoriasis Area and Severity Index (PASI) and Dermatology Quality of Life Index (DLQI) scores in psoriasis patients with controlled disease activity is non-inferior (NI) to usual care...
May 8, 2017: BMC Dermatology
https://www.readbyqxmd.com/read/28471576/adaptation-and-validation-of-the-israeli-version-of-the-chronic-urticaria-quality-of-life-questionnaire-cu-q2ol
#20
Aharon Kessel, Yael Graif, Zahava Vadasz, Vered Schichter-Konfino, Meital Almog, Shai Cohen, Valery Teplitski, Nili Stein, Ilaria Baiardini, Marcus Maurer, Elias Toubi
BACKGROUND: Chronic urticaria (CU) is a common disabling disorder. The CU-Q2oL (Chronic Urticaria Quality of Life Questionnaire) is a specific questionnaire for evaluating quality of life in CU patients. It consists of 23 items divided into six quality-of-life dimensions. It was initially developed in Italy and later validated in other countries. OBJECTIVES: To validate and adapt the CU-Q2oL to the Hebrew language in order to make it suitable for use in Israel. METHODS: The CU-Q2oL questionnaire was translated to Hebrew...
August 2016: Israel Medical Association Journal: IMAJ
keyword
keyword
15510
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"